Encap Announces Significant Capital Expenditure Program
Encap Drug Delivery recently announced a $2-million capital expenditure program to support its growing CMO activities. Following the earlier expansion in 2008 when the company completed a $3-million investment involving an expansion of the Oakbank Park Way facility to provide two additional clean room suites, including a High Potency facility and further expansion of its development laboratories, Encap is now providing new investment for additional high-volume manufacturing equipment.
During the last 24 months, Encap has experienced a 20% increase in sales of its Pharmaceutical Development Services (PDS) and commercial manufacturing (CMO) activities and is forecasting a similar rate of growth in 2012/14. To complement the growth plans, Encap has committed a further $2 million of capital expenditure, buying the latest product mixing and capsule filling equipment, including a highly flexible Esco Labor (EL200) mixer and a high-speed Bosch filling machine (GKF2500L) and weight checker (KKE2500). Delivery of the new equipment will start this August and will be completed by February 2013.
“Encap has seen tremendous growth in its PDS business in the past 2 years with the initiation of more than 30 new pharma client projects,” said Encap’s Chief Executive Officer, Dr. Stephen Brown. “We have also recently completed the launch of three new commercial pharmaceutical products in EU and
Encap Drug Delivery is the world’s largest contract development and manufacturing organization (CDMO) totally dedicated to liquid and semi-solid (hot melt) filled capsules. The company was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing, and high-volume commercial manufacturing. For more information, visit www.encapdrugdelivery.com.
Total Page Views: 913
